NCT02712320 - Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

December 19, 2017

Conditions

Prostatic Neoplasms

Interventions

DRUG

LMIS 50 mg

Subcutaneous injection of 50 mg Leuprolide Mesylate

Trial Locations (7)

Carolina Clinical Trials, LLC, Concord

Carolina Urologic Research Center, Myrtle Beach

Urology Centers of Alabama, Homewood

Idaho Urologic Institute - Meridian, Meridian

Genesis Research, LLC, San Diego

Seattle Urology Research Center, Burien

AdvanceMed Research, Lawrenceville